An Update on the Diagnosis and Management of Hereditary Angioedema With Abnormal C1 Inhibitor
February 2015 | Volume 14 | Issue 2 | Original Article | 151 | Copyright © 2015
Mark Davis-Lorton MD
Division of Rheumatology, Immunology and Allergy, Winthrop-University Hospital, Mineola, NY
Hereditary angioedema (HAE) is a rare genetic disease caused by a deficiency in functional C1-esterase inhibitor characterized by recurrent episodes of angioedema in the absence of associated urticaria. Subcutaneous swellings are experienced by virtually all patients
with HAE, and dermatologists are likely to encounter this manifestation, requiring that they be knowledgeable about diagnosis and
treatment options. Diagnosis of HAE is often delayed because several of the symptoms can mimic other disease states. Delays in
diagnosis can lead to increased inappropriate treatment and decreased patient quality of life. Once a proper diagnosis is made, treatment
needs to be targeted to the individual patient and includes on-demand therapy and an option for short- and long-term prophylaxis.
On-demand therapy is required for all patients who are diagnosed with HAE and effective options include plasma-derived and recombinant
C1 inhibitors, kallikrein inhibitors, and bradykinin B2-receptor antagonists. Options available for prophylaxis include plasma-derived
C1 inhibitors, attenuated androgens, and antifibrinolytic agents, although the latter 2 options are associated with significant adverse
events. This article reviews the diagnosis and options for effective management of patients with HAE.
J Drugs Dermatol. 2015;14(2):151-157.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Hereditary angioedema (HAE) is a rare genetic disease caused by a deficiency in functional C1-esterase inhibitor (C1 INH) characterized by recurrent episodes of nonpruritic, subcutaneous, or submucosal edema commonly involving the bowels, genitalia, trunk, extremities, face, tongue, or larynx.1,2 The estimated frequency of HAE is 1 in 50,000 individuals in the general population without differences in race or sex.1 There are 2 primary types of HAE associated with abnormal levels of C1 INH. Type I, characterized by decreased levels of C1 INH antigen in the plasma, accounts for approximately 85% of cases. Type II is characterized by the expression of a dysfunctional C1 INH protein with normal or slightly elevated levels of C1 INH antigen, and accounts for approximately 15% of cases.2,3 Distinctly, a third type of HAE, deemed HAE with normal C1 INH, has been described in patients who express normal functioning C1 INH but suffer the classic recurrent attacks of angioedema.4 Although in the United States, most HAE patient’s care is managed by allergists and clinical immunologists, most urticaria and angioedema may be seen first by dermatologists, requiring a clear understanding of HAE and its therapeutic management. In contrast, the majority of European patients are under the care of dermatologists and hematologists. This review will focus on the diagnosis and management of patients with HAE with CI INH deficiency.
C1 INH is a serine protease inhibitor that inhibits several complement proteases including C1r, C1s, and mannan-binding lectin-associated proteases (MASPs) 1 and 2. C1 INH also inactivates plasma kallikrein, and coagulation factors XIa and XIIa, thereby regulating activation of the contact system and the intrinsic coagulation pathway.3 Regulation of these systems is performed through the formation of complexes between the proteases and the inhibitor, resulting in inactivation of both and consumption of the C1 INH. HAE patients already have low levels of endogenous or functional C1 INH and further consumption may trigger an attack. Without enough C1 INH to regulate the contact system, the activation of kallikrein goes unchecked and cleaves high-molecular-weight kininogen, which frees the potent mediator responsible for the vascular permeability, bradykinin (Figure 1).
Angioedematous episodes usually begin in patients between the ages of 5 and 11 years, with the majority of the first episodes beginning by age 20, but they may occur at any age5 (Figure 2). HAE should be suspected in patients with recurrent angioedema or abdominal pain in the absence of associated urticaria. HAE attacks are commonly preceded by a prodrome, usually a tingling sensation.2 In addition, erythema marginatum, a nonpruritic, serpiginous rash, accompanies about one third of HAE attacks. Subcutaneous swellings are the most common angioedematous episodes (Figure 3). Abdominal swellings affecting the submucosa of the bowel, which are associated with severe pain, nausea, and vomiting, are also frequently seen and can be very incapacitating. A laryngeal